SOPHiA GENETICS (SOPH) EBIT (2020 - 2025)

SOPHiA GENETICS (SOPH) has 6 years of EBIT data on file, last reported at -$18.5 million in Q4 2025.

• For the quarter ending Q4 2025, EBIT fell 6.15% year-over-year to -$18.5 million; the trailing twelve-month figure through Dec 2025 stood at -$70.9 million (down 6.52% YoY), and the FY2025 full-year result was -$70.9 million, down 6.52% from the prior year.
• EBIT declined to -$18.5 million in Q4 2025, from -$17.9 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$14.1 million in Q1 2021 to a low of -$25.0 million in Q1 2022.
• A 5-year average of -$18.6 million and a median of -$18.5 million in 2025 frame the typical range for EBIT.
• Peak annual rise in EBIT reached 99.77% in 2021, while the deepest fall reached 217289.46% in 2021.
• Tracing SOPH's EBIT over 5 years: stood at -$21.0 million in 2021, then increased by 28.21% to -$15.1 million in 2022, then fell by 25.61% to -$18.9 million in 2023, then gained by 7.93% to -$17.4 million in 2024, then retreated by 6.15% to -$18.5 million in 2025.
• Business Quant data shows SOPH's EBIT at -$18.5 million in Q4 2025, -$17.9 million in Q3 2025, and -$18.5 million in Q2 2025.